ORMP (STOCKS)
Oramed Pharmaceuticals Inc.
$4.380000
+0.110000 (+2.58%)
Prev close: $4.270000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Nadav Kidron
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $182.20M
- Employees
- 13
- P/E (TTM)
- 1.04
- P/B (TTM)
- 0.56
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.24 | $0.00 | +0.2447 | +0.00% |
|
Sep 2025 (Q3)
|
$1.12 | $-0.04 | +1.1608 | +2,845.10% |
|
Jun 2025 (Q2)
|
$0.31 | $-0.04 | +0.3508 | +859.80% |
|
Mar 2025 (Q1)
|
$-0.19 | $-0.01 | -0.1798 | -1,762.75% |
Financial Statements
| Nonoperating Income/Loss | $225.24M |
| Operating Income/Loss | -$14.52M |
| Income/Loss From Continuing Operations After Tax | $174.86M |
| Income/Loss From Continuing Operations Before Tax | $220.28M |
| Income Tax Expense/Benefit | $45.41M |
| Income Tax Expense/Benefit, Current | $6.04M |
| Net Income/Loss | $174.86M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$6.00K |
| Net Income/Loss Attributable To Parent | $174.87M |
| Net Income/Loss Available To Common Stockholders, Basic | $174.06M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $808.00K |
| Preferred Stock Dividends And Other Adjustments | $808.00K |
| Basic Earnings Per Share | $4.24 |
| Diluted Earnings Per Share | $4.13 |
| Basic Average Shares | 82,497,848 |
| Diluted Average Shares | 84,460,085 |
| Assets | $369.64M |
| Current Assets | $53.41M |
| Noncurrent Assets | $316.24M |
| Fixed Assets | $532.00K |
| Other Non-current Assets | $315.70M |
| Liabilities | $52.17M |
| Current Liabilities | $10.73M |
| Accounts Payable | $374.00K |
| Wages | $340.00K |
| Other Current Liabilities | $10.02M |
| Noncurrent Liabilities | $41.44M |
| Equity | $317.47M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $317.47M |
| Liabilities And Equity | $369.64M |
| Net Cash Flow From Operating Activities | -$5.21M |
| Net Cash Flow From Operating Activities, Continuing | -$5.21M |
| Net Cash Flow From Investing Activities | $21.50M |
| Net Cash Flow From Investing Activities, Continuing | $21.50M |
| Net Cash Flow From Financing Activities | -$16.68M |
| Net Cash Flow From Financing Activities, Continuing | -$16.68M |
| Exchange Gains/Losses | -$165.00K |
| Net Cash Flow | -$552.00K |
| Net Cash Flow, Continuing | -$387.00K |
| Comprehensive Income/Loss | $174.86M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $174.86M |
| Other Comprehensive Income/Loss | $0.00 |